Protocol Review: Assessing Acupuncture for Chemotherapy-Induced Diarrhoea in Colorectal Cancer

The Clinical Need: Acupuncture for Chemotherapy-Induced Diarrhoea

Colorectal cancer protocols demand high physiological resilience. Chemotherapy-induced diarrhoea (CID) represents a significant operational failure in patient management, not merely a side effect. It disrupts treatment schedules, necessitates dose reductions, and increases mortality risks. Current pharmacological interventions often lack precision or introduce secondary complications. Consequently, the medical community is investigating acupuncture for chemotherapy-induced diarrhea as a targeted, non-pharmacological adjunct. The urgent question is whether traditional techniques can withstand the rigour of modern evidence-based oncology. This new protocol outlines a method to aggregate scattered data into a coherent clinical directive.

Systematic Evaluation Strategy

This document analyses a registered protocol (PROSPERO CRD420251045610), establishing the framework for a future meta-analysis. The investigators will execute a sweep of eight major electronic repositories, including PubMed, Embase, and the Cochrane Central Register (CENTRAL). To avoid geographic bias, the search strategy includes Chinese databases like CNKI and Wanfang, with zero language restrictions.

The objective is to isolate Randomised Controlled Trials (RCTs) specifically targeting colorectal cancer patients. Quality control is paramount. Two independent reviewers will utilise the Cochrane Risk of Bias tool (RoB2) to filter low-quality evidence. Disagreements will face third-party adjudication. This rigorous filtering process ensures that only robust, verifiable data informs the final synthesis.

Metrics of Success

How will efficacy be defined? The review rejects vague anecdotal reports in favour of hard metrics. Primary endpoints focus on the tangible reduction of symptoms:

• Severity: Quantified via the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS).
• Duration: Measured by the reduction in time of diarrhoeal episodes.

Secondary endpoints will evaluate the broader patient experience. Safety assessments will track acupuncture-related adverse reactions, while quality of life will be measured using the EORTC QLQ-C30 questionnaire. Data synthesis will occur via Review Manager (RevMan 5.3). This statistical approach allows for the calculation of pooled effects, determining if individual small-scale successes translate into a broad clinical recommendation.

Strategic Implications for Oncology

The outcomes of this systematic review could dictate future supportive care standards. If the data confirms efficacy, acupuncture may transition from an optional integrative therapy to a recommended standard for maintaining dose intensity. CID is a primary driver of treatment non-compliance. By potentially mitigating this toxicity without adding to the pharmacological load, acupuncture could stabilise the therapeutic window. This protocol serves as the necessary audit. It separates signal from noise, determining if the intervention offers a viable, evidence-based solution for a debilitating complication.